Singh Nimisha, Marets Célia, Boudon Julien, Millot Nadine, Saviot Lucien, Maurizi Lionel
Laboratoire Interdisciplinaire Carnot de Bourgogne (ICB), UMR 6303 CNRS - Université Bourgogne Franche-Comté BP 47870 Dijon Cedex F-21078 France
Nanoscale Adv. 2021 Jan 13;3(5):1209-1229. doi: 10.1039/d0na00863j. eCollection 2021 Mar 9.
Nanomaterials have a huge potential in research fields from nanomedicine to medical devices. However, surface modifications of nanoparticles (NPs) and thus of their physicochemical properties failed to predict their biological behavior. This requires investigating the "missing link" at the nano-bio interface. The protein corona (PC), the set of proteins binding to the NPs surface, plays a critical role in particle recognition by the innate immune system. Still, incubation offers a limited understanding of biological interactions and fails to explain the fate. To date, several reports explained the impact of PC but its applications in the clinical field have been very limited. Furthermore, PC is often considered as a biological barrier reducing the targeting efficiency of nano vehicles. But the protein binding can actually be controlled by altering PC both and . Analyzing PC could accordingly provide a deep understanding of its biological effect and speed up the transfer to clinical applications. This review demonstrates the need for clarifications on the effect of PC and the control of its behavior by changing its physicochemical properties. It unfolds the recent developments to understand mechanisms and challenges at the nano-bio interface. Finally, it reports recent advances in the PC to overcome and control the limitations of the PC by employing PC as a boosting resource to prolong the NPs half-life, to improve their formulations and thereby to increase its use for biomedical applications.
Biotechnol Adv. 2017-8-26
Acc Chem Res. 2021-1-19
Int J Pharm. 2022-2-25
Front Bioeng Biotechnol. 2020-4-3
Biomed Pharmacother. 2021-7
Adv Mater. 2018-12-27
Trends Biotechnol. 2016-9-20
Adv Colloid Interface Sci. 2021-3
Front Drug Deliv. 2024-8-8
Biomimetics (Basel). 2025-4-29
Nanoscale Adv. 2020-1-9
ACS Biomater Sci Eng. 2015-11-9
J Control Release. 2020-10-10